The effect of 0.05% Cyclosporine A eyedrops in patients after cataract surgery

Efficacy of 0.05% Cyclosporine A on the lipid layer and meibomian gland after cataract surgery: a randomized, double-masked study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10173448

Enrollment

Registered

2020-04-06

Start date

2019-04-04

Completion date

Unknown

Last updated

2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye syndrome, meibomian gland dysfunction Eye Diseases

Interventions

Eligible patients are randomized using the random number method into two treatment groups. The first group will use 0.05% CsA ophthalmic emulsion (Restasis®, Allergan Inc., Irvine, CA) twice daily ove

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult cataract patients with normal lid position and closure and not suffering from any ocular diseases

Exclusion criteria

Exclusion criteria: 1. Patients who had used topical anti-inflammatory, antibiotic, or other medication during the previous 90 days before surgery 2. Eyes with a history of trauma, ocular surgery, laser or systemic treatment known to affect tear secretion, autoimmune disease, current use of contact lenses, and/or history of slit-lamp evidence of eye surface disorders

Design outcomes

Primary

Measure	Time frame
At baseline and three months. 1. Ocular surface status parameters: 1.1. Lipid layer thickness (LLT) using an interferometer 1.2. Schirmer’s type I test 1.3. Tear breakup time (TBUT) 2. Ocular Surface Disease Index (OSDI) questionnaire to evaluate the patients’ symptoms 3. Meiboscores with the LipiView® interferometer to calculate the degree of meibomian gland dysfunction	—

Countries

Korea, South

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026